ATS 2025: A Proof of Concept Therapeutic Solution for Chronic Cough: Personalized Monitoring and Targeted Suppression

Unmet needs in chronic cough are significant, affecting millions globally:

• ~7M RCC/UCC patients in the US (~200M globally)
• No approved antitussive drugs for RCC/UCC
• Guideline‑recommended behavioral therapy for RCC/UCC is proven - just largely unavailable (<250 providers in the US)

Behavioral Cough Suppression Therapy (BCST) is Proven To Work

• >15 studies (4 RCTs, 11+ prospective cohorts/series, 4 languages) with ~500 unique patients evaluated
• Mean LCQ improvement: +4 - 7.5 points (3-4x MCID)
• Mean 24-h cough-count reduction: 30-50% (41% in largest RCT)
• No adverse events - excellent safety

Digital Therapeutic Opportunity - why now?

• Proven mechanism – neuroplastic retraining of cough reflex
• Compelling effect size – equal or superior to top antitussive molecules in development, potential for “software + pill”
• No safety liabilities
• Telehealth validation – 88% responder rate in video-BCST cohort
• Pathways to reimbursement are increasing worldwide

WHAT IT IS?

• Digitally delivered behavioral cough suppression therapy (BCST)
• Designed for high engagement to promote strong adherence
• Continuous, passive cough monitoring
• Biofeedback loop enabling tailored personalization

HOW IT WORKS?

• AI passively monitors cough frequency and patterns
• App delivers proven techniques to suppress cough
• Real-time efficacy tracking and biofeedback enables personalization and ensures adherence

CLINICALLY & COMMERCIALLY VALIDATED

• BCST has demonstrated up to 88% effectiveness in reducing cough frequency
• Safe, easy, and with zero side effects
• In development as a prescription-only regulated SaMD for the Japanese market

‍